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doi:10.1016/j.jtcvs.2003.12.034TObjective: Both vascular endothelial growth factor and cyclooxygenase 2 overex-
pression have been associated with poor prognosis in a variety of human malig-
nancies. In this study we assessed the effect of preoperative chemotherapy and
radiation on expression levels of vascular endothelial growth factor and cyclooxy-
genase 2 in patients with esophageal cancer and determined whether these markers
were associated with treatment response and overall survival.
Methods: Expression levels of vascular endothelial growth factor and cyclooxygen-
ase 2 were measured in a cohort of 46 patients with esophageal cancer receiving
preoperative chemoradiation followed by surgical resection. Immunohistochemical
stains were performed on both pretreatment biopsy specimens and posttreatment
resection specimens for each patient. Differences in vascular endothelial growth
factor and cyclooxygenase 2 expression before and after treatment were measured,
and pretreatment expression levels were correlated with treatment response and
overall survival.
Results: We found that preoperative chemotherapy and radiation induced expression
of cyclooxygenase 2 in stromal cells and induced vascular endothelial growth factor
expression in both tumor and stromal cells. Pretreatment vascular endothelial
growth factor expression did not correlate with treatment response, and cyclooxy-
genase 2 expression correlated with treatment response only in the subset of patients
with squamous cell carcinoma. Although patients whose tumors expressed high
levels of vascular endothelial growth factor and cyclooxygenase 2 tended to have
shorter overall survival times, this trend did not reach statistical significance.
Conclusions: Neither vascular endothelial growth factor nor cyclooxygenase 2 are
strong predictors of treatment response and survival in patients undergoing preop-
erative chemoradiation for esophageal cancer. This lack of prognostic significance
might be explained by changes in the expression levels of these markers during
treatment.
Esophageal cancer is the cause of more than 12,000 deaths in theUnited States per year and is increasing in incidence.1 Unfortunately,only 10% of patients given a diagnosis of esophageal cancer arecured of their disease. Preoperative chemotherapy and external beamradiation is a common form of treatment for patients who havesurgically resectable and therefore potentially curable esophageal
cancer. With this approach, patients who achieve complete pathologic responses
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who do not respond.2,3 This observation has led to the
investigation of markers that might help predict response to
preoperative chemotherapy and radiation and thus might
allow selection of patients who could benefit from an ag-
gressive treatment regimen.
Both tumor cells and surrounding stromal cells are
known to secrete a variety of cytokines and growth factors,
many of which have been shown to have long-term prog-
nostic significance. One such cytokine is vascular endothe-
lial growth factor (VEGF), which induces endothelial cell
proliferation and vascular permeability and is associated
with increased microvessel density.4,5 VEGF is overex-
pressed in several human solid tumor types, including 30%
to 60% of esophageal cancers.6-9 In patients undergoing
surgical resection for squamous cell carcinoma of the
esophagus, multiple studies have demonstrated a correlation
between high levels of VEGF expression, advanced stage,
and poor overall survival.6-10
The value of VEGF expression as a predictor of treat-
ment response in patients receiving preoperative chemother-
apy and radiation therapy for esophageal cancer is less clear.
Two studies have suggested that VEGF overexpression is
associated with resistance to treatment.11,12 A third study,
however, failed to confirm these findings.13 Furthermore, a
study examining microvessel density in patients with esoph-
ageal cancer receiving preoperative chemoradiation showed
no correlation with treatment response or survival.14 These
studies suggest that VEGF is a less useful prognostic marker
in patients undergoing preoperative therapy.
Cyclooxygenase 2 (COX-2) expression has also been
evaluated, both as a potential predictor of response to che-
motherapy and radiation and as a predictor of overall sur-
vival. COX-2 is one of several enzymes responsible for
arachidonic acid metabolism and is induced by a number of
growth factors and cytokines.15 COX-2 has been implicated
in the promotion of angiogenesis, inhibition of cell-cycle
control, and resistance to apoptosis.15,16 COX-2 overexpres-
sion has also been associated with resistance to preoperative
systemic cisplatin-based chemotherapy and concurrent ra-
diation therapy in patients with squamous cell carcinoma of
the cervix and has been shown to predict shorter survival
times in patients with cancers of the stomach, breast, blad-
der, cervix, ovary, and head and neck.17-23 In patients with
esophageal adenocarcinoma undergoing surgical resection,
COX-2 overexpression has been associated with a higher
probability of metastasis and shorter overall survival
times.24 The value of COX-2 as a prognostic factor in
patients with esophageal cancer undergoing preoperative
chemotherapy and radiation has not been studied.
Although both VEGF and COX-2 overexpression are
clear adverse prognostic factors in other settings, the poten-
tial for preoperative therapy to induce changes in the ex-
1580 The Journal of Thoracic and Cardiovascular Surgery ● Junpression levels of VEGF and COX-2 might diminish their
utility as prognostic factors in patients receiving such treat-
ment. We therefore measured VEGF and COX-2 expression
in esophageal cancer tissue and tumor-associated stroma
from 46 patients, all of whom had received preoperative
chemotherapy and radiation. We determined whether the
pretreatment expression levels were associated with either
treatment response or overall survival and assessed whether
preoperative therapy induced changes in the expression
levels of these markers.
Materials and Methods
Patients
The study group consisted of 46 patients with esophageal cancer
who were identified through a review of medical records as having
received concurrent neoadjuvant chemotherapy and radiation fol-
lowed by esophageal resection at the Brigham and Women’s
Hospital between 1989 and 1995 and for whom both pretreatment
biopsy specimens and posttreatment resection specimens could be
evaluated for marker expression. The study was conducted with
institutional review board approval. Follow-up survival and dis-
ease recurrence data were available for all patients and were
obtained either through a review of patient charts or by contacting
the patients directly.
Specimen Collection
All esophageal resection specimens were received in the surgical
pathology laboratory in the fresh state and then fixed in 10%
buffered formalin for subsequent tissue sectioning. The specimens
were sectioned according to a standard protocol, which included a
minimum of 3 sections through the deepest portion of the tumor,
a minimum of 3 sections through the proximal and distal margins
of resection, and a thorough lymph node sampling. For cases in
which no gross tumor was identified (eg, patients with complete
pathologic response after chemotherapy and radiation), the entire
area of ulcerated or otherwise abnormal-appearing tissue was
submitted for histologic evaluation.
Tissue Analysis
Five-micrometer-thick tissue sections of tumor were cut from
formalin-fixed, paraffin-embedded tissue blocks and used for fur-
ther immunohistochemical analysis. Stromal tissue immediately
adjacent to tumor tissue was also analyzed on the same slide. One
of the authors (J.D.M.) reviewed all of the slides in a blinded
manner. Immunohistochemical detection of COX-2 was performed
by using the tyramide signal amplification indirect amplification
method.25 The sections were deparaffinized and rehydrated and
sequentially treated to block endogenous peroxidase (3% hydrogen
peroxide in methanol) and biotin (avidin-biotin blocking kit, no.
SP-2001, Vector Corp). The sections were then incubated with a
monoclonal antibody for COX-2 (Caymen Chemical) at 4°C over-
night, followed by incubation with a labeled polymer, horseradish
peroxidase (anti-mouse) (DAKO Corp), for 1 hour. Tissue sections
were then treated in strepavidin-peroxidase for 30 minutes at room
temperature, incubated with biotinylated tyramide at a 1:50 dilu-
tion for 15 minutes at room temperature, and finally incubated in
strepavidin-peroxidase for 30 minutes at a dilution of 1:250. After
e 2004
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the sections were dehydrated and placed in coverslips. A case of
colon carcinoma known to strongly express COX-2 was used as a
positive control. Omission of the primary antibody was used as the
negative control. The cases were scored according to the propor-
tion of either tumor or stromal cells that stained for COX-2 (0,
negative; 1, 33%; 2, 34%-66%; and 3, 67%).
Immunohistochemistry for VEGF was carried out by using a
rabbit polyclonal antibody for VEGF (VEGF A-20, Santa Cruz
Antibodies) at a 1:100 dilution after antigen retrieval by means of
the microwave technique (750 W for 5 minutes in pH 6.0 citrate
buffer). The secondary antibody and development were combined
in the DAKO EnVision system (DAKO Corp). A light hema-
toxylin stain was used as the counterstain. A case of colon carci-
noma known to strongly express VEGF was used as a positive
control. Omission of the primary antibody was used as a negative
control. The scoring of VEGF expression was based on the Ger-
man Reactive Scoring System, in which the intensity of staining
was graded on a scale of 0 to 3 (0, no staining; 1, weak; 2,
moderate; and 3, strong), and the percentage of stained cells was
graded on a scale of 0 to 4 (0, 0; 1, 1%-10%; 2, 11%-50%; 3,
51%-80%; and 4, 81%-100%).26 The intensity and percentage of
cells that stained positive were multiplied to arrive at a final score
that ranged from 0 to 12.
The microvessel density of the tumors and stroma was evalu-
ated by examining CD31 expression. A monoclonal antibody for
CD31 (Neomarkers, Inc) was incubated with the tissue sections at
4°C overnight at a 1:500 dilution, followed by incubation with a
biotinylated anti-mouse antibody for 1 hour at a 1:100 dilution.
The reaction was developed with an avidin-biotin development
system, followed by a light hematoxylin counterstaining. Mi-
crovessel density was calculated according to previously published
procedures.27 The areas of tumor with the most extensive neovas-
cularization, termed hot spots, were identified by scanning stained
slides at low power. These areas were generally found at the
periphery, or the deepest invasive margin, of the tumor. In these
hot spot areas, the number of microvessels was counted per 40
microsopic field. At least 3 different 40 fields, or hot spots, were
evaluated for each case to obtain the mean microvessel count for
TABLE 1. Clinical and pathologic features of the study po
Mean age (y)
Male/female
Median follow-up (mo)
Response to neoadjuvant therapy
Complete pathologic response
Partial pathologic response (microscopic residual tumor)
No response (gross residual tumor)
Clinical status
Alive without disease
Alive with disease
Dead of disease
Dead of other causeseach patient.
The Journal of ThoracicStatistical Methods
Data analyses were performed with STATA software (Stata Press).
Matched comparisons between pretreatment and posttreatment ex-
pression and between expression in tumor and stroma or inflam-
matory tissue were tested with the signed-rank test. Nonmatched
comparisons were tested with the Mann-Whitney test. The prog-
nostic significance of various expression levels was tested with the
Cox regression model.
Results
Clinical and Pathologic Features of the Study
Population
Of the 46 patients in the study, 28 had adenocarcinoma, and
18 had squamous cell carcinoma (Table 1). The mean age
was 62 years, and there was a clear male preponderance
(male/female ratio, 35:11). The median follow-up was 18
months (range, 1-77 months) for the 28 patients with ade-
nocarcinoma and 13 months (range, 1-35 months) for the 18
patients with squamous cell carcinoma. All patients were
confirmed through a medical record review to have received
preoperative concurrent chemotherapy and radiation.
Twelve (26%) patients had complete pathologic responses
to neoadjuvant therapy, with no residual tumor cells present
in the resection specimen. Thirteen (29%) patients had a
partial response to therapy (microscopic residual tumor),
and 21 (46%) patients had minimal or no response to
therapy (gross residual tumor). Because several patients had
received their preoperative chemotherapy outside our insti-
tution, the specific preoperative chemotherapy regimens
were obtainable in only 31 (67%) patients. As anticipated,
the majority (28 [90%] patients) received treatment with the
standard regimen of cisplatin, 5-fluorouracil, and external
beam radiation. The remaining 3 (10%) patients received
5-fluorouracil alone in combination with external beam
tion
denocarcinoma
(n  28)
Squamous cell
carcinoma
(n  18)
Total
(n  46)
(range, 39-80) 62 (range, 51-78) 62 (range, 39-80)
24:4 11:7 35:11
(range, 1-77) 13 (range, 1-35) 16 (range, 1-77)
9 (32%) 3 (17%) 12 (26%)
6 (21%) 7 (39%) 13 (28%)
13 (46%) 8 (44%) 21 (46%)
15 (54%) 10 (56%) 25 (54%)
0 1 (6%) 1 (2%)
12 (43%) 6 (33%) 18 (39%)
1 (4%) 1 (6%) 2 (4%)pula
A
63
18radiation.
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Tumor VEGF expression was evaluated in 46 pretreatment
biopsy specimens. The proportion of tumors expressing
VEGF significantly increased after preoperative treatment:
before treatment, 28 (61%) of 46 biopsy specimens ex-
pressed VEGF; after treatment, 19 (95%) of 20 specimens
expressed VEGF (Table 2). The mean level of VEGF ex-
pression, as measured by the mean VEGF expression score,
also increased after treatment, from a pretreatment level of
3.0 to a posttreatment level of 7.9. (P  .0002).
In 26 cases posttreatment tumor specimens could not be
evaluated for VEGF staining because of treatment effect,
resulting in either insufficient tumor cells for accurate anal-
ysis or, in the case of complete responders, absent residual
tumor cells. We therefore separately evaluated the VEGF
staining scores in the 20 patients who had tumors that could
be evaluated both before and after treatment. VEGF expres-
sion was present in 12 (60%) of 20 of these patients, a
proportion that did not significantly differ from the overall
cohort. The distribution of VEGF staining scores in these 20
patients illustrates the increase in both the number of pos-
itively staining tumors and in the intensity of VEGF expres-
sion after preoperative therapy (Figure 1, A).
Preoperative treatment also induced VEGF expression in
tumor-associated stromal cells (Table 2). Stromal cells
could be evaluated for VEGF expression in 46 cases both
before and after treatment. Preoperative therapy resulted in
an increase in the proportion of stromal cells expressing
TABLE 2. Changes in VEGF and COX-2 expression before
VEGF expression
Before treatment
N
Cases expressing
VEGF (%) ex
Tumor
Adenocarcinoma 28 18 (64)
SCCa 18 10 (56)
Total 46 28 (61)
Tumor-associated stroma
Adenocarcinoma 28 16 (57)
SCCa 18 11 (61)
Total 46 27 (59)
COX-2 expression N
Cases expressing
COX-2 (%) ex
Tumor
Adenocarcinoma 28 11 (39)
SCCa 18 13 (72)
Total 46 24 (52)
Tumor-associated stroma
Adenocarcinoma 28 10 (36)
SCCa 18 0 (0)
Total 46 10 (22)
VEGF, Vascular endothelial growth factor; COX-2, Cyclooxygenase 2; SCCVEGF: before treatment, stromal VEGF expression was
1582 The Journal of Thoracic and Cardiovascular Surgery ● Junobserved in 27 (59%) of 46 cases; after therapy, 46 (100%)
of 46 cases expressed VEGF. The mean VEGF expression
score increased from a pretreatment level of 0.76 to a
posttreatment level of 3.7 (P  .0001). The distribution of
stromal VEGF expression scores illustrates the increase in
both the number of tumors expressing VEGF and in the
VEGF staining intensity after preoperative treatment (Fig-
ure 1, B). Representative VEGF staining results for both
tumor and stroma are shown in Figure 2, A.
COX-2 Expression
Tumor COX-2 expression could be evaluated in 46 pretreat-
ment biopsy specimens and in 25 posttreatment resection
specimens (Table 2). No significant induction of tumor
COX-2 expresssion was observed. COX-2 expression was
noted in 24 (52%) of 46 tumors before treatment compared
with 16 (64%) of 25 tumors after treatment. The mean
COX-2 expression score before therapy was 0.65 compared
with 0.86 after therapy, a difference that did not reach
statistical significance.
In 21 cases posttreatment COX-2 levels could not be
evaluated after treatment because of insufficient or absent
residual tumor cells. Of the 25 cases that could be evaluated
for expression both before and after treatment, 10 (40%)
overexpressed COX-2, a proportion that did not differ sig-
nificantly from the overall cohort. When the distribution of
COX-2 expression scores was analyzed in these 25 tumors
before and after treatment, no clear difference in overall
after preoperative chemoradiation
After treatment
n VEGF
sion score N
Cases expressing
VEGF (%)
Mean VEGF
expression score
.8 12 11 (92) 8.3 (P .007)
.3 8 8 (100) 7.3 (P .01)
.0 20 19 (95) 7.9 (P .0002)
.82 28 28 (100) 3.3 (P .0001)
.67 18 18 (100) 4.4 (P .0002)
.76 46 46 (100) 3.7 (P .0001)
n COX-2
sion score N
Cases expressing
COX-2 (%)
Mean COX-2
expression score
.41 16 10 (63) 0.78 (P .19)
.0 9 6 (67) 1.0 (P .95)
.65 25 16 (64) 0.86 (P .28)
.52 28 22 (79) 1.3 (P .003)
18 16 (89) 1.4 (P .0002)
.32 46 38 (83) 1.4 (P .0001)
amous cell carcinoma.and
Mea
pres
2
3
3
0
0
0
Mea
pres
0
1
0
0
0
0
a, Squstaining intensity was noted (Figure 1, C).
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pretreatment biopsy specimens and posttreatment resection
specimens of all 46 cases (Table 2). Preoperative therapy
resulted in significant induction of stromal COX-2 expres-
sion. Before treatment, 10 (36%) of 46 cases expressed
COX-2 compared with 38 (83%) of 46 cases after treatment.
The mean stromal COX-2 expression score increased from
a pretreatment level of 0.32 to a posttreatment level of 1.4
(P  .0001). The distribution of stromal COX-2 expression
scores further illustrates the increase in both the proportion
and intensity of stromal COX-2 staining after treatment
(Figure 1, D). Representative COX-2 staining results for
both tumor and stroma are shown in Figure 2, B.
Stromal Microvessel Density
We anticipated that increased stromal VEGF and COX-2
expression would correlate closely with increased angiogen-
esis and increased microvessel density in stromal tissue.
Measurements of stromal CD31 expression in our samples
confirmed that stromal microvessel density increased in
parallel with VEGF and COX-2 expression: the mean mi-
crovessel density score in 38 cases that could be evaluated
was 17.2 before treatment compared with 20.6 after preop-
Figure 1. Distribution of staining scores in cases tha
chemotherapy and radiation: A, VEGF tumor (n  20); B
stroma (n  46). White bars, pretreatment; black barserative therapy (P  .02).
The Journal of ThoracicPrognostic Significance of VEGF and COX-2
Expression
Low levels of tumor COX-2 before treatment were predic-
tive for treatment response, defined as complete pathologic
response, among patients with squamous cell carcinoma
(Table 3). Pretreatment levels of tumor COX-2 were not
predictive of response among patients with adenocarci-
noma. We found no correlation between pretreatment tumor
VEGF expression and response to therapy. Patients with
high pretreatment levels of VEGF and COX-2 tended to
have shorter overall survival times; however, this trend did
not reach statistical significance.
Discussion
In this study we evaluated the effect of preoperative che-
moradiation on VEGF and COX-2 expression in patients
with esophageal cancer and assessed whether pretreatment
expression levels correlated with treatment response or
overall survival. We found no association between VEGF
expression and treatment response. Although absence of
COX-2 expression was associated with complete pathologic
response in the subset of patients with squamous cell car-
uld be evaluated both before and after preoperative
GF stroma (n  46); C, COX-2 tumor (n  25); D, COX-2
ttreatment.t co
, VE
, poscinoma, there was no correlation between COX-2 expres-
and Cardiovascular Surgery ● Volume 127, Number 6 1583
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whose tumors expressed COX-2 and VEGF before treat-
ment tended to have shorter median survival times, but these
differences did not reach statistical significance.
Most previous studies have found that VEGF overex-
pression is an adverse prognostic factor in patients with
esophageal cancer. This association is presumably due to
the fact that increased tumor angiogenesis reflects more
aggressive clinical behavior.6-11 At least 2 small studies of
preoperative chemoradiation in patients with esophageal
cancer have suggested an association between high VEGF
levels and poor prognosis.11,12 Interestingly, a larger Japa-
Figure 2. Expression of VEGF and COX-2 before and a
staining with antibodies to VEGF. A preoperative biop
cells (blue arrow) or stroma (red arrow). A posttreatmen
staining in epithelial cells (blue arrow), as well as stai
both photos.) B, Immunohistochemical staining with
demonstrates scattered positive epithelial cells (blue a
resection specimen of the same case demonstrates sta
arrow). (Original magnification 400 for both photos.)nese study of 73 patients with esophageal cancer receiving
1584 The Journal of Thoracic and Cardiovascular Surgery ● Junpreoperative chemoradiation failed to find such an associa-
tion.13 Similarly, although we noted a tendency for patients
with VEGF overexpression to have shorter median survival
times, this association did not reach statistical significance.
The lack of a clear correlation between pretreatment
VEGF levels and either treatment response or survival in
these studies might, in part, be explained by our observation
that preoperative chemotherapy and radiation induce ex-
pression of VEGF. Such induction results in increased an-
giogeneic activity, as demonstrated by a parallel increase in
microvessel density. Similar findings have been reported in
studies of human xenografts, which have demonstrated that
reoperative chemoradiation. A, Immunohistochemical
ecimen demonstrates no staining of either epithelial
ection specimen of the same case demonstrates strong
of stroma (red arrow). (Original magnification 400 for
ibodies to COX-2. A preoperative biopsy specimen
and no staining in stroma (red arrow). A posttreatment
in epithelial cells (blue arrow), as well as stroma (redfter p
sy sp
t res
ning
ant
rrow)
iningtreatment, particularly radiation, induces VEGF expression,
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ment-resistant tumor cells.28,29 These models suggest that
the treatment-induced development of more aggressive and
resistant tumor phenotypes might weaken potential associ-
ations between pretreatment VEGF levels, treatment re-
sponse, and overall survival.
Unlike VEGF expression, which increased in both tumor
and stromal tissue after preoperative treatment with chemo-
therapy and radiation, COX-2 expression increased in tu-
mor-associated stroma and inflammatory cells but remained
relatively stable in the tumor tissue that remained after
therapy. We found that low COX-2 expression was associ-
ated with complete pathologic response in the subset of
patients with squamous cell carcinoma of the esophagus.
This observation is limited by the relatively small number of
patients who could be evaluated in this cohort but is con-
sistent with recent findings in patients undergoing treatment
for squamous cell carcinoma of the cervix, in which COX-2
overexpression was also associated with resistance to che-
moradiation.20 We found no association between COX-2
expression and treatment response in patients with adeno-
carcinoma. As with VEGF, the tendency for patients with
COX-2 overexpression to have shorter median survival
times did not reach statistical significance. Whether the
induction of COX-2 in tumor-associated stromal tissue
might also lead to the development of treatment resistance
and weaken a potential association between pretreatment
tumor levels of COX-2 and survival is uncertain.
In summary, we found that VEGF expression is not
predictive of treatment response and does not strongly cor-
relate with survival in patients undergoing preoperative
chemoradiation for esophageal cancer. Low levels of
COX-2 expression do appear to correlate with treatment
TABLE 3. Association between pretreatment expression l
patients with esophageal cancer
Tumor type N
Number (%) with complete pathologic
preoperative therapy as a function
expression
COX-2 positive COX-2 negative
Adenocarcinoma 28 4/11 (36) 5/17 (29)
Squamous cell
carcinoma
18 0/13 (0) 3/5 (60)
Total 46 4/24 (17) 8/22 (36)
VEGF positive VEGF negative
Adenocarcinoma 28 6/18 (33) 3/10 (30)
Squamous cell
carcinoma
18 3/10 (30) 0/8 (0)
Total 46 9/28 (32) 3/18 (17)
P value for response rate was determined by using the Fisher’s exact te
Mann-Whitney test. COX-2, Cyclooxygenase 2; VEGF, vascular endotheliaresponse in the subset of patients with squamous cell car-
The Journal of Thoraciccinoma but, like VEGF, do not strongly correlate with
survival. Changes in the expression levels of VEGF and
COX-2 induced by preoperative therapy might explain their
lack of strong prognostic value.
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